PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of elranatamab for multiple myeloma, CPX-351 for myeloid leukemia, inotuzumab ozogamicin for lymphoblastic leukemia, capivasertib for breast cancer, and zolbetuximab for gastric cancer in Japan

Int J Clin Oncol. 2024 Apr 30. doi: 10.1007/s10147-024-02531-1. Online ahead of print.NO ABSTRACTPMID:38687406 | DOI:10.1007/s10147-024-02531-1

Source: Clinical Genitourinary Cancer - April 30, 2024 Category: Cancer & Oncology Authors: Noriomi Matsumura Masaki Mandai Source Type: research